Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life (LONG-LIFE)
An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life
The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults.
Up to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period.
Findings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of psilocybin on relevant study endpoints.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Aging is accompanied by progressive changes across multiple physiological systems that contribute to functional decline and increased risk for age-related disease. Biomarkers of biological aging, including DNA methylation-based epigenetic clocks, have emerged as tools for assessing age-related biological processes and predicting future health outcomes.
Recent preclinical studies have suggested that psilocybin and its active metabolite, psilocin, may influence several pathways implicated in aging, including cellular senescence, oxidative stress, neuroplasticity, and epigenetic regulation. In addition to biological effects, observational studies have demonstrated associations between psychosocial factors, including purpose in life and social connectedness, and reduced morbidity and mortality in older adults. Previous clinical studies have shown that psilocybin may produce changes in psychological well-being, meaning, and related constructs.
The LONG-LIFE Study is designed to evaluate multiple domains relevant to healthy aging, including, but not limited to, epigenetic and biological clock measures, cognitive performance, psychosocial well-being, and ecological momentary assessments of daily experience.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: BHIC Study Team
- Numero di telefono: 970-855-7374
- Email: bhic@vailhealth.org
Luoghi di studio
-
-
Colorado
-
Edwards, Colorado, Stati Uniti, 81632
- Vail Health Behavioral Health
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- English speaking and able to provide informed consent and complete study procedures
- Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.
Exclusion Criteria:
- History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results.
- Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).
- Unwilling or unable to discontinue medications that may interfere with study participation, as determined by the investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: One 25mg Dose of Psilocybin
Participants in this arm will receive one 25mg dose of psilocybin paired with therapeutic support.
|
25mg capsule of psilocybin
|
|
Sperimentale: Two 25mg Doses of Psilocybin
Participants in this arm will receive two 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.
|
25mg capsule of psilocybin
|
|
Sperimentale: Three 25mg Doses of Psilocybin
Participants in this arm will receive three 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.
|
25mg capsule of psilocybin
|
|
Nessun intervento: Wait-list Comparator
Participants in this arm will not receive psilocybin as part of the main study but will be given the opportunity to receive a single 25mg dose of psilocybin with therapeutic support after their study participation is complete.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Epigenetic/Biological Clock Profiling from Baseline to Week 4 and Week 16
Lasso di tempo: Change from Baseline to Week 4 and Week 16
|
Epigenetic/biological clock profiles; change from Baseline to Week 4 and 16
|
Change from Baseline to Week 4 and Week 16
|
|
Change in Purpose in Life (PIL) from Baseline to Week 4 and Week 16
Lasso di tempo: Change from Baseline to Week 4 and Week 16
|
Change from baseline in Purpose in Life score measured using the 7-item Purpose in Life Scale (PIL) from the Health and Retirement Study (score range 1-6; higher scores indicate greater purpose in life).
|
Change from Baseline to Week 4 and Week 16
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Epigenetic/Biological Clock Profiling from Baseline to Week 52
Lasso di tempo: Change from Baseline to Week 52
|
Change in Epigenetic/biological clock profile from Baseline to Week 52
|
Change from Baseline to Week 52
|
|
Change in Telomere Length from Baseline to Week 52
Lasso di tempo: Change from Baseline to Week 52
|
Change from Baseline to Week 52
|
|
|
Change in Purpose in Life (PIL) from Baseline to Week 52
Lasso di tempo: Change from Baseline to Week 52
|
Change from baseline in Purpose in Life score measured using the 7-item Purpose in Life Scale (PIL) from the Health and Retirement Study (score range 1-6; higher scores indicate greater purpose in life).
|
Change from Baseline to Week 52
|
|
Change in Satisfaction with Life from Baseline to Week 4 and Week 16
Lasso di tempo: Change from Baseline to Week 4 and Week 16
|
Measured using the Satisfaction With Life Scale (SWLS).
Scores range from 5 to 35, where higher scores indicate greater satisfaction with life.
|
Change from Baseline to Week 4 and Week 16
|
|
Change in Wellbeing from Baseline to Week 4 and Week 16
Lasso di tempo: Change from Baseline to Week 4 and Week 16
|
Measured using the Warwick Edinburgh Mental Well-Being Scale (WEMWBS).
Scores range from 14 to 70, with higher scores indicating higher mental wellbeing.
|
Change from Baseline to Week 4 and Week 16
|
|
Change in Optimism from Baseline to Week 4 and Week 16
Lasso di tempo: Change from Baseline to Week 4 and Week 16
|
Measured using the Life Orientation Test - Revised (LOT-R).
Scores range from 0 to 24, with higher scores indicating higher dispositional optimism.
|
Change from Baseline to Week 4 and Week 16
|
|
Change in Perceived Control/Mastery from Baseline to Week 4 and Week 16
Lasso di tempo: Change from Baseline to Week 4 and Week 16
|
Measured using the Pearlin Mastery Scale (PM).
Scores range from 7 to 28; higher totals indicate greater self-mastery.
|
Change from Baseline to Week 4 and Week 16
|
|
Change in Loneliness from Baseline to Week 4 and Week 16
Lasso di tempo: Change from Baseline to Week 4 and Week 16
|
Measured using the 3-Item UCLA Loneliness Scale (UCLA-3).
Scores range from 3 to 9. Higher scores indicate a greater degree of loneliness.
|
Change from Baseline to Week 4 and Week 16
|
Collaboratori e investigatori
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 20262840
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .